Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The funding will advance the development of OSSM-007, an interferon-gamma primed mesenchymal stem cell product, for the treatment of Steroid-Refractory Acute Graft versus Host Disease (GVHD), with plans to initiate clinical study activities by the end of 2023.
Lead Product(s): OSSM-007
Therapeutic Area: Immunology Product Name: OSSM-007
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: California Institute of Regenerative Medicine
Deal Size: $3.4 million Upfront Cash: Undisclosed
Deal Type: Funding April 28, 2023
Details:
OSSM-001, a mesenchymal stem cell (MSC) product is the second Ossium cell therapy product to enter the clinic, for the treatment of refractory perianal fistulas in patients with Crohn’s disease.
Lead Product(s): Mesenchymal Stem Cell
Therapeutic Area: Gastroenterology Product Name: OSSM-001
Highest Development Status: IND EnablingProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 16, 2022